- United States
- Our innovation
Our innovation
We innovate with purpose to lead where medicine is going.
Our focus areas
Our discovery, product development and supply process
With our cross-functional approach to innovation, deep expertise, and global footprint, we aim to develop therapies for patients by inventing, licensing and acquiring new molecular entities and exploring new pathways and multi-modality treatment approaches.
23-255-richard-tillyer-part-1-who-we-are-1.mp4
23-255-richard-tillyer-part-1-who-we-are-1.mp4
Research & development
We believe there are no limits to what science can do. We work to bring breakthroughs beyond medicine to help transform patients’ lives.
Our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Data science and digital health
Data science and digital health accelerate our R&D engine across the entire value-chain – from target discovery and patient segmentation to drug design, CMC process optimization and all facets of clinical development.
Latest news
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet therapy regimen shows significant improvement in outcomes for patients with transplant-eligible newly diagnosed multiple myeloma
DARZALEX FASPRO®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen First presentation of data from Phase 3 PERSEUS study highlighted in late-breaking abstract session at ASH 2023 and simultaneously published in The New England Journal of Medicine
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T Additional presentations at the 2023 ASH Annual Meeting showed potential improvement in adverse events among patients who received reduced intensity dosing and first-ever results from TALVEY™ combination study
Contact us
Our R&D leadership team is made up of passionate individuals who are helping to transform the future of healthcare.